High-Throughput Liquid Chromatography–Tandem Mass Spectrometry Quantification of Glycosaminoglycans as Biomarkers of Mucopolysaccharidosis II
Authors:
- Junhua WangJWJunhua Wang
- Akhil BhallaAkhil Bhalla
- Julie C. UllmanJUJulie C. Ullman
- Meng FangMFMeng Fang
- Ritesh RaviRRRitesh Ravi
- Annie ArguelloAAAnnie Arguello
- Elliot ThomsenETElliot Thomsen
- Buyankhishig TsogtbaatarBTBuyankhishig Tsogtbaatar
- Jing L. GuoJGJing L. Guo
- Lukas L. SkujaLSLukas L. Skuja
- Jason C. DugasJDJason C. Dugas
- Sonnet S. DavisSDSonnet S. Davis
Open Access
- 30 July 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (15) , 5449
Abstract
We recently developed a blood–brain barrier (BBB)-penetrating enzyme transport vehicle (ETV) fused to the lysosomal enzyme iduronate 2-sulfatase (ETV:IDS) and demonstrated its ability to reduce glycosaminoglycan (GAG) accumulation in the brains of a mouse model of mucopolysaccharidosis (MPS) II. To accurately quantify GAGs, we developed a plate-based high-throughput enzymatic digestion assay coupled with liquid chromatography–tandem mass spectrometry (LC-MS/MS) to simultaneously measure heparan sulfate and dermatan sulfate derived disaccharides in tissue, cerebrospinal fluid (CSF) and individual cell populations isolated from mouse brain. The method offers ultra-high sensitivity enabling quantitation of specific GAG species in as low as 100,000 isolated neurons and a low volume of CSF. With an LOD at 3 ng/mL and LLOQs at 5–10 ng/mL, this method is at least five times more sensitive than previously reported approaches. Our analysis demonstrated that the accumulation of CSF and brain GAGs are in good correlation, supporting the potential use of CSF GAGs as a surrogate biomarker for brain GAGs. The bioanalytical method was qualified through the generation of standard curves in matrix for preclinical studies of CSF, demonstrating the feasibility of this assay for evaluating therapeutic effects of ETV:IDS in future studies and applications in a wide variety of MPS disorders.Keywords
This publication has 44 references indexed in Scilit:
- Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and IIIMolecular Genetics and Metabolism, 2012
- Simultaneous Analysis of Heparan Sulfate, Chondroitin/Dermatan Sulfates, and Hyaluronan Disaccharides by Glycoblotting-Assisted Sample Preparation Followed by Single-Step Zwitter-Ionic-Hydrophilic Interaction ChromatographyAnalytical Chemistry, 2011
- Analysis of Glycosaminoglycans in Cerebrospinal Fluid from Patients with Mucopolysaccharidoses by Isotope-Dilution Ultra-Performance Liquid Chromatography–Tandem Mass SpectrometryClinical Chemistry, 2011
- Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidoses and mucolipidoses II and III by tandem mass spectrometryMolecular Genetics and Metabolism, 2010
- Organ-specific Heparan Sulfate Structural PhenotypesJournal of Biological Chemistry, 2009
- Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compressionAmerican Journal of Medical Genetics Part A, 2008
- Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycansNature Methods, 2008
- Enzymatic Degradation of GlycosaminogIycansCritical Reviews in Biochemistry and Molecular Biology, 1995
- Lack of relationship between blood and urine levels of glycosaminoglycans and lysomal enzymesBiochemical Medicine, 1975
- Acid mucopolysaccharides in the cerebrospinal fluid of patients with Hunter–Hurler's syndromeJournal of Neurochemistry, 1970